Add Reply
Add Comment As A Guest
Close Topic OptionsNovartis
Novartis - Psychology, Special Needs, Health - Posted: 19th Feb, 2014 - 12:30am
Posts: 6 - Views: 739
PharmaceuticalsPost Date: 26th Jan, 2010 - 1:56pm / Post ID: #
NOTE: Informer [?]
Novartis
Vasella steps down as Novartis chief
Health / Medicine Related News
Daniel Vasella is to give up his role as chief executive of the Swiss pharmaceuticals group to concentrate on the chairmanship
Source: FT.com - Pharmaceuticals
Novartis (Hover)
Sponsored Links:
Post Date: 12th Mar, 2013 - 4:30am / Post ID: #
NOTE: Informer [?]
Novartis
Ex-Novartis chief Vasella to move to US
Sector veteran switches national residence just weeks after stepping down as chairman of Swiss pharmaceuticals heavyweight he had headed for 17 years
Source: Pharmaceuticals companies news from the Financial Times
Post Date: 2nd Apr, 2013 - 4:30am / Post ID: #
NOTE: Informer [?]
Novartis Health & Special Psychology
Novartis loses Indian patent case
Supreme Court rules that the active ingredient in cancer drug Glivec is a known compound, and is therefore ineligible for a patent
Source: Pharmaceuticals companies news from the Financial Times
Post Date: 10th Dec, 2013 - 4:30am / Post ID: #
NOTE: Informer [?]
Novartis
New Novartis Chair Undoes Vasella Regime
Jörg Reinhardt, who replaced Daniel Vasella as chairman of Novartis, is rolling back many of the hands-on practices of his predecessor
Source
Post Date: 18th Feb, 2014 - 4:30am / Post ID: #
NOTE: Informer [?]
Novartis
Novartis Presses India On Intellectual Property
Swiss drugmaker's chief Jimenez urges India to focus on intellectual property rights, claiming its present stance deters investment
Source
Post Date: 19th Feb, 2014 - 12:30am / Post ID: #
NOTE: Informer [?]
Novartis
Novartis To Buy U.S.-based Biotech CoStim For Undisclosed Price
Biotechnology News
ZURICH (Reuters) - Novartis said it will buy U.S.-based CoStim Pharmaceuticals Inc., a privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer, for an undisclosed price. The Swiss drugmaker said the move follows increasing evidence pointing to the role of the immune system in controlling cancer. (Reporting By Katharina Bart; Editing by John Stonestreet)
Source
TOPIC: Novartis